Marc J Lajoie

USPTO Granted Patents = 16 (Patent Applications = 15)

EPO Patents = 1 (Patent Applications = 2)

Average Co-Inventor Count = 5.0

ph-index = 3

Forward Citations = 20(Granted Patents)

Location History:

Cambridge, MA (US) (2017 - 2022)
Seattle, WA (US) (2019 - 2024)

Company Filing History:

University of Washington

patents

3 out of 5

Lyell Immunopharma, Inc.

patents

4. 2 out of 8,396

Massachusetts Institute of Technology

patents

5. 2 out of 1,650

University of Utah Research Foundation

patents

where one patent can have more than one assignee

Years Active: 2017-2025

Loading Chart...

16 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12304927 - De novo design of protein switches (2025-05-20),

2. 12270032 - Codon-optimized nucleotide sequences encoding an AP-1 transcription factor (2025-04-08),

3. 12234572 - Split interleukin mimetics and their use (2025-02-25),

4. 12144827 - ROR1 targeting chimeric antigen receptor (2024-11-19),

5. 12130281 - Gene editing through microfluidic delivery (2024-10-29),

6. 12054531 - Recombinant cell surface markers (2024-08-06),

7. 11866699 - Genome editing reagents and their use (2024-01-09),

8. 11361845 - Methods for rule-based genome design (2022-06-14),

9. 11125739 - Gene editing through microfluidic delivery (2021-09-21),

10. 11028383 - Polypeptide assemblies and methods for the production thereof (2021-06-08),

11. 10910085 - Methods of making polypeptides with non-standard amino acids using genomically recoded organisms (2021-02-02),

12. 10851135 - De novo design of protein switches (2020-12-01),

13. 10570400 - Methods of introducing nucleic acids into cellular DNA (2020-02-25),

14. 10501733 - Polypeptide assemblies and methods for the production thereof (2019-12-10),

15. 9834775 - Recombinant cells and organisms having persistent nonstandard amino acid dependence and methods of making them (2017-12-05),

Title: The Innovative Contributions of Marc J Lajoie

Introduction

Marc J Lajoie is a prominent inventor based in Cambridge, MA, known for his significant contributions to the field of biotechnology. With a total of 16 patents to his name, Lajoie's work focuses on the design and application of protein switches and nucleotide sequences that have the potential to revolutionize therapeutic approaches, particularly in treating diseases such as cancer.

Latest Patents

Among his latest patents is the "De novo design of protein switches," which describes innovative protein switches capable of sequestering bioactive peptides and binding domains in an inactive state. These switches can be activated by a second designed polypeptide, referred to as the key, which induces a conformational change to activate the bioactive component. Another notable patent is for "Codon-optimized nucleotide sequences encoding an AP-1 transcription factor." This patent discloses polynucleotides that include a nucleotide sequence encoding the AP-1 transcription factor, c-Jun, and may also comprise additional sequences for various functional domains. These inventions have broad implications for developing cells, vectors, and pharmaceutical compositions aimed at treating various diseases.

Career Highlights

Marc J Lajoie has had a distinguished career, working at prestigious institutions such as Harvard College and the University of Washington. His research has significantly advanced the understanding of protein engineering and gene therapy, making him a key figure in the biotechnology sector.

Collaborations

Throughout his career, Lajoie has collaborated with notable scientists, including David Baker and George M Church. These collaborations have further enhanced the impact of his research and innovations in the field.

Conclusion

Marc J Lajoie's contributions to biotechnology through his innovative patents and collaborations have positioned him as a leading inventor in his field. His work continues to inspire advancements in therapeutic applications and protein engineering.

This text is generated by artificial intelligence and may not be accurate.